

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 53011

**Title:** Complete response in anaplastic lymphoma kinase-rearranged oncocyctic thyroid cancer: A case report and review of literature

**Reviewer's code:** 02476743

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Associate Professor, Statistician

**Reviewer's Country/Territory:** Taiwan

**Author's Country/Territory:** France

**Manuscript submission date:** 2020-01-18

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-01-23 03:14

**Reviewer performed review:** 2020-01-30 06:40

**Review time:** 7 Days and 3 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgooffice@wjgnet.com](mailto:bpgooffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

Overall comments: This case report was discussed the complete response to crizotinib in anaplastic lymphoma kinase-rearranged oncocyctic thyroid cancer. There are several areas where the manuscript needs to be strengthened. Specific comments: 1.Statement of Ethics: In addition to Institutional Review Board approval, authors should also state that subject have given their written informed consent 2. More discussion regarding the medical policy implications of their findings would be essential for the use of methodology in medical decision making. 3.The authors should add the comments related to selection bias in this study to the perceived limitation subsection. Totally, I would like to congratulate the authors for the enthusiasm invested in this study. However, the manuscript does not reach the level of quality required for publication as original research without major revision in World Journal of Clinical Oncology.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 53011

**Title:** Complete response in anaplastic lymphoma kinase-rearranged oncocyctic thyroid cancer: A case report and review of literature

**Reviewer's code:** 02498816

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** France

**Manuscript submission date:** 2020-01-18

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-01-19 00:22

**Reviewer performed review:** 2020-01-30 09:58

**Review time:** 11 Days and 9 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

I read this manuscript with interest. In addition, ALK-positive thyroid cancer is extremely rare. So I think that this case report seems to be important for medical clinician. However, I have several comments. 1) Authors should describe the response by using radiographic criteria.(RECIT criteria). Several reports showed the biological (or metabolic ) complete response by ALK or EGFR-tyrosine -kinase inhibitor in patients with lung cancer. I think “Complete response to crizotinib by PET findings” is not essential in this paper. Title should be changed. 2) Authors should show the pathological findings of thyroid tumor and ALK positive pictures (IHC or FISH).

## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 53011

**Title:** Complete response in anaplastic lymphoma kinase-rearranged oncocyctic thyroid cancer: A case report and review of literature

**Reviewer's code:** 02476743

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Associate Professor, Statistician

**Reviewer's Country/Territory:** Taiwan

**Author's Country/Territory:** France

**Manuscript submission date:** 2020-01-18

**Reviewer chosen by:** Ying Dou

**Reviewer accepted review:** 2020-05-21 02:01

**Reviewer performed review:** 2020-05-22 01:50

**Review time:** 23 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

Overall comments: This case report was discussed the complete response to crizotinib in anaplastic lymphoma kinase-rearranged oncocytic thyroid cancer. There are several areas where the manuscript needs to be strengthened. Specific comments: 1.Statement of Ethics: In addition to Institutional Review Board approval, authors should also state that subject have given their written informed consent 2. More discussion regarding the medical policy implications of their findings would be essential for the use of methodology in medical decision making. 3.The authors should add the comments related to selection bias in this study to the perceived limitation subsection. 4.Some references should be updated. Totally, I would like to congratulate the authors for the enthusiasm invested in this study. However, the manuscript does not reach the level of quality required for publication as original research without major revision in World Journal of Clinical Oncology.